CoChat
Sign Up
Cited by 97CAR-T cell therapy researchT-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Toward an optimized process for clinical manufacturing of CAR-treg cell therapy

Open access
Fritsche, Enrico, Volk, Hans-Dieter, Reinke, Petra, Abou-El-Enein, Mohamed·2020·Trends in Biotechnology
DOI 10.1016/j.tibtech.2019.12.009
Open this paper in CoChat — free accountOpen PDF

Abstract

Chimeric antigen receptor (CAR) technology and its application to regulatory T cells (Tregs) has garnered interest among researchers in the field of cell and gene therapy. Merging the benefits of CAR technology with Tregs offers a novel and promising therapeutic option for durable reshaping of undesired immune responses following solid organ or hematopoietic stem cell transplantation, as well as in immune-related disorders. However, major challenges remain for developing a standardized and robust good manufacturing practice (GMP)-compliant manufacturing process for CAR-Treg cells. We review current progress in the field and recommend ways to improve CAR-Treg manufacturing processes based on lessons learned from first-generation Treg therapeutics as well as from anticancer CAR-T cell development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tibtech.2019.12.009

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Moving toward functionally closed and fully automated manufacturing platforms may enable production scalability and reduce potential human error.

    “Moving toward functionally closed and fully automated manufacturing platforms may enable production scalability and reduce potential human error (71).”

    From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [71]

    The passage labeled Abstract (page unavailable) describes a move toward nearly closed, (semi)automatic systems and says these reduce costs and batch-to-batch variability. It does not say that such platforms enable production scalability or reduce human error; its separate discussion of scaling up concerns medium supply. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 106 · Cited by 97

Part of this paper’s reference list could not be split into single entries.

Research works printed but not linked: 95

  1. [1]1. Edinger, M. Driving allotolerance: CAR-expressing Tregs for tolerance induction in organ and stem cell transplantation J. Clin. Invest. 2016; 126:1248-1250 Crossref Scopus (5) PubMed Google Scholar
  2. [2]2. Bluestone, J.A. ∙ Tang, Q. T reg cells – the next frontier of cell therapy Science. 2018; 362:154-155 Crossref Scopus (33) PubMed Google Scholar
  3. [3]3. Romano, M. ... Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity Front. Immunol. 2019; 10:43 Crossref Scopus (51) PubMed Google Scholar
  4. [4]4. June, C.H. ∙ Sadelain, M. Chimeric antigen receptor therapy N. Engl. J. Med. 2018; 379:64-73 Crossref Scopus (374) PubMed Google Scholar
  5. [5]5. Krause, A. ... Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes J. Exp. Med. 1998; 188:619-626 Crossref Scopus (141) PubMed Google Scholar
  6. [6]6. Sakaguchi, S. ... Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases J. Immunol. 1995; 155:1151-1164 Crossref PubMed Google Scholar
  7. [7]7. Trzonkowski, P. ... First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127− T regulatory cells Clin. Immunol. 2009; 133:22-26 Crossref Scopus (392) PubMed Google Scholar
  8. [8]8. Sawitzki, B.S. ... Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials Lancet. 2020; 395:1627-1639 Full Text Full Text (PDF) Scopus (7) PubMed Google Scholar
  9. [9]9. MacDonald, K.G. ... Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor J. Clin. Invest. 2016; 126:1413-1424 Crossref Scopus (147) PubMed Google Scholar
  10. [10]10. Boardman, D.A. ... Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection Am. J. Transplant. 2017; 17:931-943 Crossref Scopus (80) PubMed Google Scholar
  11. [11]11. Zhang, Q. ... Chimeric antigen receptor (CAR) Treg: a promising approach to inducing immunological tolerance Front. Immunol. 2018; 9:2359 Crossref Scopus (19) PubMed Google Scholar
  12. [13]13. Bèzie, S. ... Human CD8+ Tregs expressing a MHC-specific CAR display enhanced suppression of human skin rejection and GVHD in NSG mice Blood Adv. 2019; 3:3522-3538 Crossref Scopus (3) PubMed Google Scholar
  13. [14]14. Arroyo Hornero, R. ... CD45RA distinguishes CD4+CD25+CD127−/low TSDR demethylated regulatory T cell subpopulations with differential stability and susceptibility to tacrolimus-mediated inhibition of suppression Transplantation. 2017; 101:302-309 Crossref Scopus (24) PubMed Google Scholar
  14. [15]15. Landwehr-Kenzel, S. ... Ex vivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy Kidney Int. 2018; 93:1452-1464 Full Text Full Text (PDF) PubMed Google Scholar
  15. [16]16. Battaglia, M. ... Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients J. Immunol. 2006; 177:8338-8347 Crossref PubMed Google Scholar
  16. [17]17. Chandran, S. ... Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants Am. J. Transplant. 2017; 17:2945-2954 Crossref Scopus (53) PubMed Google Scholar
  17. [18]18. Dawson, N.A.J. ∙ Levings, M.K. Antigen-specific regulatory T cells: are police CARs the answer? Transl. Res. 2017; 187:53-58 Full Text Full Text (PDF) Scopus (17) PubMed Google Scholar
  18. [19]19. Abou-El-Enein, M. ... Good manufacturing practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs Cytotherapy. 2013; 15:362-383 Full Text Full Text (PDF) Scopus (31) PubMed Google Scholar
  19. [20]20. Abou-El-Enein, M. ... Putting a price tag on novel autologous cellular therapies Cytotherapy. 2016; 18:1056-1061 Full Text Full Text (PDF) PubMed Google Scholar
  20. [21]21. Abou-El-Enein, M. ... Overcoming challenges facing advanced therapies in the EU market Cell Stem Cell. 2016; 19:293-297 Full Text Full Text (PDF) PubMed Google Scholar
  21. [22]22. Abou-El-Enein, M. ... Strategies for derisking translational processes for biomedical technologies Trends Biotechnol. 2017; 35:100-108 Full Text Full Text (PDF) Scopus (12) PubMed Google Scholar
  22. [23]23. Mathew, J.M. ... A Phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants Sci. Rep. 2018; 8:7428 Crossref Scopus (44) PubMed Google Scholar
  23. [24]24. Abou-El-Enein, M. ... Clinical Development of cell therapies: setting the stage for academic success Clin. Pharmacol. Ther. 2017; 101:35-38 Crossref Scopus (9) PubMed Google Scholar
  24. [26]26. Iyer, R.K. ... Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges Front. Med. 2018; 5:150 Crossref Scopus (22) PubMed Google Scholar
  25. [28]28. Cobbold, S. ∙ Waldmann, H. Infectious tolerance Curr. Opin. Immunol. 1998; 10:518-524 Crossref Scopus (215) PubMed Google Scholar
  26. [29]29. Levine, B.L. ... Global manufacturing of CAR T cell therapy Mol. Ther. - Methods Clin. Dev. 2017; 4:92-101 Full Text Full Text (PDF) Scopus (165) PubMed Google Scholar
  27. [30]30. Vormittag, P. ... A guide to manufacturing CAR T cell therapies Curr. Opin. Biotechnol. 2018; 53:164-181 Crossref Scopus (55) PubMed Google Scholar
  28. [31]31. Boroughs, A.C. ... Chimeric antigen receptor costimulation domains modulate human regulatory T cell function JCI Insight. 2019; 5:126194 Crossref Scopus (15) PubMed Google Scholar
  29. [32]32. Koristka, S. ... Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology J. Autoimmun. 2018; 90:116-131 Crossref Scopus (20) PubMed Google Scholar
  30. [33]33. Elinav, E. ... Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice Gastroenterology. 2008; 134:2014-2024 Full Text Full Text (PDF) Scopus (67) PubMed Google Scholar
  31. [34]34. Elinav, E. ... Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor Gastroenterology. 2009; 136:1721-1731 Full Text Full Text (PDF) Scopus (68) PubMed Google Scholar
  32. [35]35. Bailey, S.R. ∙ Maus, M.V. Gene editing for immune cell therapies Nat. Biotechnol. 2019; 37:1425-1434 Crossref Scopus (25) PubMed Google Scholar
  33. [36]36. Ramanayake, S. ... Low-cost generation of good manufacturing practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials Cytotherapy. 2015; 17:1251-1267 Full Text Full Text (PDF) PubMed Google Scholar
  34. [37]37. Monjezi, R. ... Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors Leukemia. 2017; 31:186-194 Crossref Scopus (74) PubMed Google Scholar
  35. [38]38. Singh, H. ... A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19 Immunol. Rev. 2014; 257:181-190 Crossref Scopus (88) PubMed Google Scholar
  36. [39]39. Hudecek, M. ... Minicircle-based engineering of chimeric antigen receptor (CAR) T cells Recent Results Cancer Res. 2016; 209:37-50 Crossref Scopus (7) PubMed Google Scholar
  37. [40]40. Gogol-Döring, A. ... Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the MLV retrovirus and the piggyBac transposon in primary human CD4+ T cells Mol. Ther. 2016; 24:592-606 Full Text Full Text (PDF) PubMed Google Scholar
  38. [41]41. Marín Morales, J.M. ... Automated clinical grade expansion of regulatory T cells in a fully closed system Front. Immunol. 2019; 10:38 Crossref Scopus (5) PubMed Google Scholar
  39. [42]42. Medvec, A.R. ... Improved expansion and in vivo function of patient T cells by a serum-free medium Mol. Ther. - Methods Clin. Dev. 2018; 8:65-74 Full Text Full Text (PDF) Scopus (10) PubMed Google Scholar
  40. [44]44. Wan, Y.Y. ∙ Flavell, R.A. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression Nature. 2007; 445:766-770 Crossref Scopus (626) PubMed Google Scholar
  41. [45]45. Williams, L.M. ∙ Rudensky, A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3 Nat. Immunol. 2007; 8:277-284 Crossref Scopus (605) PubMed Google Scholar
  42. [46]46. Bailey-Bucktrout, S.L. ∙ Bluestone, J.A. Regulatory T cells: stability revisited Trends Immunol. 2011; 32:301-306 Full Text Full Text (PDF) Scopus (80) PubMed Google Scholar
  43. [47]47. Hori, S. Lineage stability and phenotypic plasticity of Foxp3+ regulatory T cells Immunol. Rev. 2014; 259:159-172 Crossref Scopus (96) PubMed Google Scholar
  44. [48]48. Li, X. ∙ Zheng, Y. Regulatory T cell identity: formation and maintenance Trends Immunol. 2015; 36:344-353 Full Text Full Text (PDF) Scopus (80) PubMed Google Scholar
  45. [49]49. Rossetti, M. ... Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region J. Immunol. 2015; 194:113-124 Crossref Scopus (48) PubMed Google Scholar
  46. [50]50. Hippen, K.L. ... Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity Sci. Transl. Med. 2011; 3:83ra41 Crossref Scopus (225) PubMed Google Scholar
  47. [51]51. Okada, M. ... Stabilization of Foxp3 expression by CRISPR-dCas9-based epigenome editing in mouse primary T cells Epigenetics Chromatin. 2017; 10:24 Crossref Scopus (39) PubMed Google Scholar
  48. [52]52. Zenclussen, A.C. ... Abnormal T-cell reactivity against paternal antigens in spontaneous abortion Am. J. Pathol. 2005; 166:811-822 Full Text Full Text (PDF) PubMed Google Scholar
  49. [53]53. Canavan, J.B. ... A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy Blood. 2012; 119:e57-e66 Crossref Scopus (60) PubMed Google Scholar
  50. [54]54. Wendering, D.J. ... The value of a rapid test of human regulatory T cell function needs to be revised Front. Immunol. 2019; 10:150 Crossref Scopus (1) PubMed Google Scholar
  51. [55]55. Nowak, A. ... CD137+CD154− expression as a regulatory T cell (Treg)-specific activation signature for identification and sorting of stable human Tregs from in vitro expansion cultures Front. Immunol. 2018; 9:199 Crossref Scopus (15) PubMed Google Scholar
  52. [56]56. Florek, M. ... Freeze and thaw of CD4+CD25+Foxp3+ regulatory T cells results in loss of CD62L expression and a reduced capacity to protect against graft-versus-host disease PLoS One. 2015; 10, e0145763 Crossref Scopus (14) PubMed Google Scholar
  53. [57]57. Aijaz, A. ... Biomanufacturing for clinically advanced cell therapies Nat. Biomed. Eng. 2018; 2:362-376 Crossref Scopus (28) PubMed Google Scholar
  54. [58]58. Green, E.A. ... Pancreatic lymph node-derived CD4+CD25+ Treg cells: highly potent regulators of diabetes that require TRANCE–RANK signals Immunity. 2002; 16:183-191 Full Text Full Text (PDF) Scopus (249) PubMed Google Scholar
  55. [59]59. Tang, Q. ... In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes J. Exp. Med. 2004; 199:1455-1465 Crossref Scopus (865) PubMed Google Scholar
  56. [60]60. Masteller, E.L. ... Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice J. Immunol. 2005; 175:3053-3059 Crossref Scopus (230) PubMed Google Scholar
  57. [61]61. Tarbell, K.V. ... Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice J. Exp. Med. 2007; 204:191-201 Crossref Scopus (267) PubMed Google Scholar
  58. [62]62. Tsang, J.Y.-S. ... Conferring indirect allospecificity on CD4+CD25+ Tregs by TCR gene transfer favors transplantation tolerance in mice J. Clin. Invest. 2008; 118:3619-3628 Crossref Scopus (171) PubMed Google Scholar
  59. [63]63. Golshayan, D. ... In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance Blood. 2007; 109:827-835 Crossref Scopus (224) PubMed Google Scholar
  60. [64]64. Nishimura, E. ... Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells Int. Immunol. 2004; 16:1189-1201 Crossref Scopus (177) PubMed Google Scholar
  61. [65]65. Brunstein, C.G. ... Adoptive transfer of umbilical cord blood-derived regulatory T cells and early viral reactivation Biol. Blood Marrow Transplant. 2013; 19:1271-1273 Full Text Full Text (PDF) Scopus (57) PubMed Google Scholar
  62. [66]66. Hoffmann, P. ... Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion Blood. 2006; 108:4260-4267 Crossref Scopus (290) PubMed Google Scholar
  63. [67]67. Wang, X. ∙ Rivière, I. Clinical manufacturing of CAR T cells: foundation of a promising therapy Mol. Ther. - Oncolytics. 2016; 3:16015 Full Text Full Text (PDF) Scopus (149) PubMed Google Scholar
  64. [68]68. Ghorashian, S. ... CD19 chimeric antigen receptor T cell therapy for haematological malignancies Br. J. Haematol. 2015; 169:463-478 Crossref Scopus (38) PubMed Google Scholar
  65. [69]69. Gill, S. ∙ June, C.H. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies Immunol. Rev. 2015; 263:68-89 Crossref Scopus (196) PubMed Google Scholar
  66. [70]70. Stephenson, M. ∙ Grayson, W. Recent advances in bioreactors for cell-based therapies F1000Research. 2018; 7:517 Crossref Scopus (1) Google Scholar
  67. [71]71. Fontenot, J.D. ... Foxp3 programs the development and function of CD4+CD25+ regulatory T cells Nat. Immunol. 2003; 4:330-336 Crossref Scopus (5383) PubMed Google Scholar
  68. [72]72. Elkord, E. Thymus-derived, peripherally derived, and in vitro-induced T regulatory cells Front. Immunol. 2014; 5:17 Crossref Scopus (14) PubMed Google Scholar
  69. [73]73. Sakaguchi, S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses Annu. Rev. Immunol. 2004; 22:531-562 Crossref Scopus (2721) PubMed Google Scholar
  70. [74]74. Larkin, J. ... Activation of CD4+CD25+ regulatory T cell suppressor function by analogs of the selecting peptide Eur. J. Immunol. 2007; 37:139-146 Crossref Scopus (23) PubMed Google Scholar
  71. [75]75. Thornton, A.M. ... Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific J. Immunol. 2000; 164:183-190 Crossref Scopus (1053) PubMed Google Scholar
  72. [76]76. Sakaguchi, S. ... Regulatory T cells: how do they suppress immune responses? Int. Immunol. 2009; 21:1105-1111 Crossref Scopus (556) PubMed Google Scholar
  73. [77]77. Golovina, T.N. ... CD28 costimulation is essential for human T regulatory expansion and function J. Immunol. 2008; 181:2855-2868 Crossref PubMed Google Scholar
  74. [78]78. Lei, H. ... Human CD45RA− FoxP3hi memory-type regulatory T cells show distinct TCR repertoires with conventional T cells and play an important role in controlling early immune activation Am. J. Transplant. 2015; 15:2625-2635 Crossref Scopus (17) PubMed Google Scholar
  75. [79]79. Blat, D. ... Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells Mol. Ther. 2014; 22:1018-1028 Full Text Full Text (PDF) Scopus (78) PubMed Google Scholar
  76. [80]80. Gorovits, B. ∙ Koren, E. Immunogenicity of chimeric antigen receptor T-cell therapeutics BioDrugs. 2019; 33:275-284 Crossref Scopus (6) PubMed Google Scholar
  77. [81]81. Bour-Jordan, H. ∙ Bluestone, J.A. Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells Immunol. Rev. 2009; 229:41-66 Crossref Scopus (149) PubMed Google Scholar
  78. [82]82. Long, A.H. ... 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors Nat. Med. 2015; 21:581-590 Crossref Scopus (483) PubMed Google Scholar
  79. [83]83. Quintarelli, C. ... Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma Oncoimmunology. 2018; 7, e1433518 Crossref Scopus (31) PubMed Google Scholar
  80. [84]84. Yang, K. ... Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling Nature. 2017; 548:602-606 Crossref Scopus (66) PubMed Google Scholar
  81. [85]85. Pickar-Oliver, A. ∙ Gersbach, C.A. The next generation of CRISPR–Cas technologies and applications Nat. Rev. Mol. Cell Biol. 2019; 20:490-507 Crossref Scopus (112) PubMed Google Scholar
  82. [86]86. Hudecek, M. ... Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side Crit. Rev. Biochem. Mol. Biol. 2017; 52:355-380 Crossref Scopus (37) PubMed Google Scholar
  83. [88]88. Schober, K. ... Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function Nat. Biomed. Eng. 2019; 3:974-984 Crossref Scopus (8) PubMed Google Scholar
  84. [89]89. Roth, T.L. ... Reprogramming human T cell function and specificity with non-viral genome targeting Nature. 2018; 559:405-409 Crossref Scopus (135) PubMed Google Scholar
  85. [90]90. Abou-El-Enein, M. ... Human genome editing in the clinic: new challenges in regulatory benefit–risk assessment Cell Stem Cell. 2017; 21:427-430 Full Text Full Text (PDF) Scopus (13) PubMed Google Scholar
  86. [92]92. Zhang, X.-H. ... Off-target effects in CRISPR/Cas9-mediated genome engineering Mol. Ther. Nucleic Acids. 2015; 4, e264 Full Text Full Text (PDF) Scopus (280) PubMed Google Scholar
  87. [94]94. Yang, H. ... One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering Cell. 2013; 154:1370-1379 Full Text Full Text (PDF) Scopus (937) PubMed Google Scholar
  88. [95]95. Nankervis, B. ... Optimizing T cell expansion in a hollow-fiber bioreactor Curr. Stem Cell Reports. 2018; 4:46-51 Crossref Scopus (6) PubMed Google Scholar
  89. [96]96. Cooper, R. ... Multi-parameter flow cytometry in manufacturing of therapeutic T cells: assessing quality and potency in different GMP-compliant generation processes for EBV-specific T cells Cytotherapy. 2018; 20:S105 Full Text Full Text (PDF) Google Scholar
  90. [97]97. Bernstroem, K.E. ... Optimized process for regulatory T cell activation and expansion using DynabeadsTM Treg CD3/CD28 for clinical applications Cytotherapy. 2016; 18:S96 Full Text Full Text (PDF) Google Scholar
  91. [99]99. Eibl, R. ... Bag bioreactor based on wave-induced motion: characteristics and applications Eibl, R. ∙ Eibl, D. (Editors) Disposable Bioreactors Springer, 2009; 55-87 Crossref Scopus (58) Google Scholar
  92. [100]100. Eyles, J.E. ... Cell therapy products: focus on issues with manufacturing and quality control of chimeric antigen receptor T-cell therapies J. Chem. Technol. Biotechnol. 2019; 94:1008-1016 Crossref Scopus (4) Google Scholar
  93. [101]101. Dawson, N.A.J. ... Functional effects of chimeric antigen receptor co-receptor signaling domains in human Tregs bioRxiv. 2019; Published online August 29, 2019 Crossref Google Scholar
  94. [102]102. Querques, I. ... A highly soluble Sleeping Beauty transposase improves control of gene insertion Nat. Biotechnol. 2019; 37:1502-1512 Crossref Scopus (9) PubMed Google Scholar
  95. [103]103. Depil, S. ... ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges Nat. Rev. Drug Discov. 2020; 19:185-199 Crossref Scopus (0) PubMed Google Scholar

Authors
Fritsche, E., Volk, H.-D., Reinke, P., & Abou-El-Enein, M.
Affiliations
Berlin-Brandenburger Centrum für Regenerative Therapien (DE)
ORCID
Venue
Trends in Biotechnology
Publisher
Elsevier BV
Published
2020-10
Volume
38
Issue
10
Pages
1099-1112
ISSN
0167-7799 (ISSN-L)
DOI
10.1016/j.tibtech.2019.12.009
OpenAlex
W3000883312
Cited by
97
References
106
Citations by year
2026: 8 · 2025: 12 · 2024: 16 · 2023: 14 · 2022: 18 · 2021: 18 · 2020: 11
FWCI
1.64
Type
journal article
Language
en
Open access
Licence
Locations
  • Trends in biotechnology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
European Commission
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
regulatory T cells, chimeric antigen receptor, cell therapy manufacturing, good manufacturing practices, solid organ transplantation, hematopoietic stem cell transplantation, immune-related diseases, cell and gene therapy
MeSH terms
Animals, Humans, Genetic Therapy, Immunotherapy, Adoptive, Cell Culture Techniques, Bioreactors, T-Lymphocytes, Regulatory, Mice, Cell Engineering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review